Loncar Cancer Immunotherapy Etf Market Value
| CNCR Etf | USD 13.56 0.34 2.57% |
| Symbol | Loncar |
The market value of Loncar Cancer Immuno is measured differently than its book value, which is the value of Loncar that is recorded on the company's balance sheet. Investors also form their own opinion of Loncar Cancer's value that differs from its market value or its book value, called intrinsic value, which is Loncar Cancer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Loncar Cancer's market value can be influenced by many factors that don't directly affect Loncar Cancer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Loncar Cancer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Loncar Cancer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Loncar Cancer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Loncar Cancer 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Loncar Cancer's etf what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Loncar Cancer.
| 10/26/2024 |
| 11/25/2024 |
If you would invest 0.00 in Loncar Cancer on October 26, 2024 and sell it all today you would earn a total of 0.00 from holding Loncar Cancer Immunotherapy or generate 0.0% return on investment in Loncar Cancer over 30 days. Loncar Cancer is related to or competes with Virtus LifeSci, Virtus LifeSci, and ALPS Medical. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by th... More
Loncar Cancer Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Loncar Cancer's etf current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Loncar Cancer Immunotherapy upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 11.54 | |||
| Value At Risk | (3.72) | |||
| Potential Upside | 4.08 |
Loncar Cancer Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Loncar Cancer's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Loncar Cancer's standard deviation. In reality, there are many statistical measures that can use Loncar Cancer historical prices to predict the future Loncar Cancer's volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.32) | |||
| Total Risk Alpha | (0.46) | |||
| Treynor Ratio | (0.07) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Loncar Cancer's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Loncar Cancer Immuno Backtested Returns
Loncar Cancer Immuno has Sharpe Ratio of -0.0631, which conveys that the entity had a -0.0631% return per unit of risk over the last 3 months. Loncar Cancer exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Loncar Cancer's Risk Adjusted Performance of (0.03), mean deviation of 1.64, and Standard Deviation of 2.14 to check out the risk estimate we provide. The etf secures a Beta (Market Risk) of 1.7, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Loncar Cancer will likely underperform.
Auto-correlation | -0.3 |
Weak reverse predictability
Loncar Cancer Immunotherapy has weak reverse predictability. Overlapping area represents the amount of predictability between Loncar Cancer time series from 26th of October 2024 to 10th of November 2024 and 10th of November 2024 to 25th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Loncar Cancer Immuno price movement. The serial correlation of -0.3 indicates that nearly 30.0% of current Loncar Cancer price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.3 | |
| Spearman Rank Test | -0.72 | |
| Residual Average | 0.0 | |
| Price Variance | 0.67 |
Loncar Cancer Immuno lagged returns against current returns
Autocorrelation, which is Loncar Cancer etf's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Loncar Cancer's etf expected returns. We can calculate the autocorrelation of Loncar Cancer returns to help us make a trade decision. For example, suppose you find that Loncar Cancer has exhibited high autocorrelation historically, and you observe that the etf is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Loncar Cancer regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Loncar Cancer etf is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Loncar Cancer etf is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Loncar Cancer etf over time.
Current vs Lagged Prices |
| Timeline |
Loncar Cancer Lagged Returns
When evaluating Loncar Cancer's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Loncar Cancer etf have on its future price. Loncar Cancer autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Loncar Cancer autocorrelation shows the relationship between Loncar Cancer etf current value and its past values and can show if there is a momentum factor associated with investing in Loncar Cancer Immunotherapy.
Regressed Prices |
| Timeline |
Pair Trading with Loncar Cancer
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Loncar Cancer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Loncar Cancer will appreciate offsetting losses from the drop in the long position's value.Moving together with Loncar Etf
| 0.61 | XLV | Health Care Select | PairCorr |
| 0.66 | VHT | Vanguard Health Care | PairCorr |
| 0.87 | IBB | iShares Biotechnology ETF | PairCorr |
| 0.87 | XBI | SPDR SP Biotech | PairCorr |
Moving against Loncar Etf
| 0.44 | RSPY | Tuttle Capital Management | PairCorr |
| 0.44 | MEME | Roundhill Investments | PairCorr |
| 0.36 | DSJA | DSJA | PairCorr |
The ability to find closely correlated positions to Loncar Cancer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Loncar Cancer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Loncar Cancer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Loncar Cancer Immunotherapy to buy it.
The correlation of Loncar Cancer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Loncar Cancer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Loncar Cancer Immuno moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Loncar Cancer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Loncar Cancer Correlation, Loncar Cancer Volatility and Loncar Cancer Alpha and Beta module to complement your research on Loncar Cancer. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Loncar Cancer technical etf analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, etf market cycles, or different charting patterns.